IPO4U — Indian IPO GMP & Intelligence Platform
Quick Jump
Use ↑ ↓ to navigate · Enter to openEsc to close
Open IPOs
ListedMainboardBSE, NSE

Sahajanand Medical Technologies IPO

Sahajanand Medical Technologies IPO on BSE, NSE. Opens 15 Oct 2026 and closes 19 Oct 2026. Price band ₹344. Lot size 43 shares. Allotment 21 Oct 2026.

View financials

Price Band

₹344

Bookbuilding IPO

Lot Size

43 Shares

Min. ₹14,792

Issue Size

₹475.48 Cr

Latest GMP

₹17(+4.94%)

Est. ₹361

IPO Timeline & Milestones

All dates anchored to Indian Standard Time (IST)

IPO Lot Size

ApplicationLotsSharesAmount
Retail (Min)143₹14,792
Retail (Max)13559₹1,92,296
S-HNI (Min)14602₹2,07,088
S-HNI (Max)672881₹9,91,064
B-HNI (Min)682924₹10,05,856

Grey Market Premium (GMP)

Positive Sentiment

₹17(+4.94%)

Quote observed

Est. Listing Price₹361
Est. Gain / Lot+₹731

Upper Price Band

₹344

Retail Lot Size

43 Shares

Min. Investment (1 Lot)

₹14,792

Est. Lot Value

₹15,523

Quick Lot & Listing Gain Simulator

Test multi-lot ASBA outlay and custom GMP scenarios for Sahajanand Medical Technologies

Open Full Calculator
1 lot (43 shares)
Est. Listing ₹361
ASBA Outlay₹14,792
Est. Value₹15,523
Est. Profit / Loss+₹731 (+4.9%)

Grey market quotes are unofficial, unregulated sentiment indicators and do not guarantee listing returns.

Historical GMP Trend

Chronological grey market premium movements

5 Quotes
20 Nov 2026₹17(+4.94%)Est. Listing ₹361
Range change: ₹0
18 Nov 202619 Nov 202620 Nov 2026
Observation DateGMP PremiumDaily TrendExpected ListingRecorded At
20 Nov 2026₹17(+4.94%)0₹36120 Nov 2026, 2:10 pm
20 Nov 2026₹17(+4.94%)0₹36120 Nov 2026, 2:00 am
19 Nov 2026₹17(+4.94%)0₹36119 Nov 2026, 1:10 pm
19 Nov 2026₹17(+4.94%)0₹36119 Nov 2026, 1:00 am
18 Nov 2026₹17(+4.94%)—₹36118 Nov 2026, 12:04 pm

Sector Benchmark · IT & Digital Services

Historical Listing-Day Performance

Listing-day debut returns compared against issue price across it & tech peers.

Sector Avg. Gain

+44.4%

Across 6 sector peers

Median Debut

+16.8%

Typical listing return

Positive Debuts

5/6

83% listed above issue

Top Sector Debut

+140%

Tata Technologies

Listing GainListing DiscountSector Avg (+44.4%)Sahajanand Me. (Current)
CompanyIssue PriceListing PriceListing Gain
Sahajanand Medical TechnologiesCurrent
₹344₹361+4.9%
Tata Technologies
₹500₹1,200+140%
Netweb Technologies
₹500₹947+89.4%
₹1,119₹1,369+22.3%
₹586₹652+11.3%
₹330₹345.5+4.7%
Zaggle Prepaid Ocean
₹164₹162-1.2%

Combines 3 tracked listed IT & Digital Services peers with historical NSE/BSE sector IPO debuts. Historical listing-day gains are shown for educational sector context only and do not guarantee future listing performance.

Sahajanand Medical Technologies IPO Financials

Restated Consolidated

Sahajanand Medical Technologies Ltd.'s revenue increased by 18% and profit after tax (PAT) rose by 175% between the financial year ending with March 31, 2026 and March 31, 2025.

Period Ended30 Jun 202631 Mar 202631 Mar 202531 Mar 2024
Assets1,309.001,276.431,094.90970.58
Total Income354.331,218.731,035.96908.59
Profit After Tax15.0969.0825.15-7.35
EBITDA48.58170.66128.02110.05
NET Worth631.72616.05545.23526.30
Reserves and Surplus706.86692.48580.71556.57
Total Borrowing320.63269.53224.96175.27

Amount in ₹ Crore

Financial Highlights

Key performance metrics from audited statements

Revenue

₹1,218.73 Cr

Profit After Tax (PAT)

₹69.08 Cr

Offer for Sale (OFS)

₹475.48 Cr

Shareholding Structure

CategoryPre IPOPost IPO
Promoter and Promoter Group40.82%36.20%
Public59.18%63.80%
Total100%100%

Company Promoters Bhargav Dhirajlal Kotadia, Dhirajlal Vallabhbhai Kotadia, Priyanka Dhirajlal Cohen and Shree Hari Trust.

About Sahajanand Medical Technologies

Company overview and operations summary

Incorporated in October 2001, Sahajanand Medical Technologies Limited is a medical technology company engaged in the development, manufacturing and marketing of technologically advanced medical devices, primarily focused on vascular intervention and structural heart intervention. Its product portfolio includes coronary stents, coronary balloons, transcatheter aortic valve implantation (TAVI) devices, occluders, renal stents and peripheral drug-coated balloons (DCBs). The Company focuses on research and development, precision manufacturing and clinically supported product innovation. Its flagship brands include Supraflex Cruz, Cocoon and Hydra, serving different areas of interventional cardiology. The Company operates three manufacturing facilities, two in India and one in Thailand, supported by two R&D centres in India and Thailand. As of June 30, 2026, it had 119 patents granted globally, 78 patent applications in the pipeline and five design registrations in India. Its products were marketed in 77 countries in Fiscal 2026, through direct, hybrid and distributor-led models, with established market presence in India, Europe and other international markets. The Company reported revenue from operations of ₹12,105.04 million in Fiscal 2026, compared with ₹10,248.79 million in Fiscal 2025 and ₹9,016.04 million in Fiscal 2024. As of June 30, 2026, it had 1,605 full-time employees, 31 consultants and 707 contract-based employees. Competitive Strengths

Compare issue dates, price bands, and sentiment with other active public issues.

View all Upcoming IPOs